Nurses provide their unique perspectives on many of the recent clinical trials and developments in cancer research.
December 2011
Older patients with advanced hematologic malignancies who receive a minimally toxic nonmyeloablative regimen before allogeneic HCT have favorable OS and PFS rates.
2011 was a banner year for the NCONN, as the membership has continued to grow and it held the 3rd Annual Changing the Face of Cancer Care Conference.
There is an ongoing debate in the oncology community about a treatment technique that involves cutting all visible cancer out of the abdomen and then flooding the cavity with heated chemotherapy drugs. The procedure -- known as cytoreductive surgery (CRS) -- followed by hyperthermic intraperitoneal chemotherapy (HIPEC), or a
People with advanced cancer should be told what end-of-life care choices are available earlier in the course of their disease.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Greenlights Niraparib/Abiraterone Acetate With Prednisone in mHSPC
2
Oral Azacitidine Yields Similar PK to Subcutaneous Azacitidine in MDS/CMML
3
Pembrolizumab Plus RT Ups T-Cell Infiltration in Early Breast Cancer
4
Teclistamab/Daratumumab Increases OS, PFS in R/R Multiple Myeloma
5
